Although several pre-clinical and genomic studies defined AR as a potential tumor suppressor of ERα-positive breast cancer with antiproliferative effect due to the cross talk between these steroid receptor signaling pathways [4], studies investigating the biological role and the clinic-pathological features of AR expression in TNBC reported conflicting results. This evidence concerns the gene ESR1 and breast carcinoma.